drugset / Trial / NCT04445844
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Phase 2
Active not recruiting
25 enrolled
Mridula George, MD
Incyte Corporation · collabNational Cancer Institute (NCI) · collabOncolytics Biotech · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012 and pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic). INCMGA00012 is a monoclonal antibody that works by attaching to the programmed cell death protein 1 (PD-1) and blocking this pathway, allowing the immune system to recognize and attack the cancer cells. Pelareorep is a type of virus called reovirus which occurs naturally and may break down cancer cells. Giving INCMGA00012 and pelareorep may slow the growth and spread of the cancer to another part of the body.
Timeline
- Start
- 2020-07-13
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelareorep | Other / unclassified | — | Intravenous |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |